Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
Alfonso J. Tafur, Board Member VAS European Independent Foundation in Angiology and Vasculearn Network, shared a post on LinkedIn:
“Excited to share work from our CAIN analysis — presenting at ISTH 2026 in Paris
Perioperative Care in Cancer
Cancer patients on blood thinners face a uniquely difficult moment when surgery can’t wait.
We pooled data from two rigorous randomized VTE trials (ADAM VTE with EVE) to ask:
What actually happens when we interrupt anticoagulation for a procedure in cancer-associated thrombosis?
What we found – 179 patients, 290 procedures:
- Bleeding risk was approximately 3 times higher with injectable LMWH (dalteparin) vs. oral apixaban
- Zero recurrent blood clots at 30 days – in any group
- Procedure ‘risk category’ alone didn’t predict who bled – the low and moderate risk group had the highest bleeding rate
The precision medicine takeaway:
Anticoagulant choice, cancer biology, and individual context all matter – and apixaban appears to offer a more manageable perioperative profile.
This is exactly the kind of individualized, data-driven decision-making that precision medicine promises — now applied to one of oncology’s most common and understudied clinical scenarios.”
Stay Updated with the Latest ISTH 2026 Updates on Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients